🔗 Share this article

As the United States continues making historic revisions to its vaccine recommendations, a particular individual appears in a surprising turn: Tracy Beth Høeg, a US-based physician and epidemiologist who first made her name by questioning coronavirus vaccines in the global health crisis and has zeroed in on alleged deaths following COVID-19 immunization in her short position at the FDA.

Planned Shifts to Pediatric Immunization Program

Public health authorities planned to announce radical revisions to the pediatric vaccination calendar recently, synchronizing the US with the Danish vaccine program, according to reports – a substantial departure that would put the US out of alignment with much of the world with insufficient data for public health gain. This reveal has been pushed back until the new year.

In place of the top vaccines chief, Tracy Beth Høeg is scheduled to speak at the meeting. She was newly appointed temporary leader of the FDA’s Center for Drug Evaluation and Research (CDER), the fifth appointee to run the office this calendar year.

Consolidating Power at the FDA

Høeg's temporary position could signify a strengthened alliance between the pharmaceutical and biologics branches as Dr. Høeg and Prasad consolidate power at the FDA – and it suggests a greater focus upon reevaluating already-approved immunizations at the FDA.

Dr. Høeg has often pushed for ending certain pediatric immunization guidelines in the US in order to be more in line with Denmark, a society with universal health coverage and a population roughly the size of Wisconsin’s.

To date public appearances, she has persisted in emphasizing on immunizations – traditionally the purview of Prasad, chief of the FDA’s vaccine center – rather than drug regulation.

Questions Over Expertise

Høeg has little discernible experience in pharmaceutical research, approval processes or management, which has been customary for past leaders of the Center for Biologics Evaluation and Research. She has been employed at the FDA as a senior adviser to the commissioner and the vaccine center since earlier this year.

“She doesn’t seem to have any of the qualifications” for overseeing the pharmaceutical oversight division, said a neurologist and psychiatrist. “She’s never run a scientific study. She is not versed in leading a major agency. She is not an expert in drug approvals.”

Previous heads of CBER would “understand laws and regulations and the science of pharmaceutical innovation”, commented Janet Woodcock. “Objectively, she doesn’t have the kind of background that prior appointees who headed the center have had.”

This division has an vast workload at the agency, Woodcock pointed out.

“Many people just pays attention on the new drug program, but the generic program approves thousands of generic medications. There’s a biologic copycat branch, non-prescription drug unit and so forth, and all of those need to be supervised,” Dr. Woodcock said. “The area you neglect, that is the part that I always told people is going to bite you.”

There is also, a significant management element to the position, which supervises over 5,000 staff members. “It’s a massive management job, if you do it right,” she said.

Agency Reaction and Controversial Policies

When asked about concerns about Høeg’s fitness for the role and whether this assignment signifies increased cooperation among regulatory chiefs on immunizations, a press secretary said that the “questions stem from flawed premises”.

“This background aligns with the functions of her position,” the spokesperson said, citing the period Høeg spent counseling the FDA commissioner on “pharmaceutical safety and oversight research, including computerized risk analysis and shot safety tracking”.

As the temporary head, Høeg assumes responsibility for the agency head's new priority voucher program, a contentious one-day therapy clearance system that reportedly concerned her predecessors. “By what process are these therapies being picked for this fast-track system? Who makes the calls?” Dr. Howard said. “There’s a lot of lack of transparency happening at the regulatory body right now.”

In general, he said, “the Food and Drug Administration appears to be shifting towards less stringent regulations of all drugs, with the exception of vaccines.”

Public Track Record on Immunizations

Concerning immunizations, Høeg has a more documented, if troubling, track record, Howard observe. She published a research paper using unconfirmed public submissions to determine the rate of myocarditis after Covid vaccination. She counseled the Florida top health official Joseph Ladapo, who was said to have modified findings to suggest COVID-19 vaccinations are riskier than they are.

Among her “desired changes” for the new administration featured revising regulations for new vaccines and halting “unnecessary” vaccines, she said after the election on a online show. At the FDA, Høeg has reportedly proposed barring adolescent males from getting Covid vaccinations.

“She’s an complete true believer who begins with her conclusions and reverse-engineers to retrofit the evidence in a extremely disingenuous, fraudulent fashion,” Howard argued.

Gaining Influence and a “Revenge Tour”

Dr. Høeg aligned with fellow skeptics, {like|